Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2025)

Insight Molecular Diagnostics' EBT Margin history spans 6 years, with the latest figure at 4249.23% for Q3 2025.

  • For Q3 2025, EBT Margin rose 750294.0% year-over-year to 4249.23%; the TTM value through Sep 2025 reached 1392.91%, up 473614.0%, while the annual FY2024 figure was 3245.14%, 157275.0% down from the prior year.
  • EBT Margin for Q3 2025 was 4249.23% at Insight Molecular Diagnostics, down from 1900.0% in the prior quarter.
  • Across five years, EBT Margin topped out at 2006.4% in Q1 2023 and bottomed at 11752.17% in Q3 2024.
  • The 5-year median for EBT Margin is 1512.59% (2023), against an average of 2230.41%.
  • The largest annual shift saw EBT Margin surged 5414713bps in 2021 before it tumbled -1023959bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 1844.74% in 2021, then tumbled by -132bps to 598.46% in 2022, then plummeted by -761bps to 5152.55% in 2023, then soared by 56bps to 2262.92% in 2024, then plummeted by -88bps to 4249.23% in 2025.
  • Per Business Quant, the three most recent readings for IMDX's EBT Margin are 4249.23% (Q3 2025), 1900.0% (Q2 2025), and 318.01% (Q1 2025).